

## WHAT IS CLAIMED IS:

- 1. A peptide comprising a sequence of less than 50 amino acids characterised in that
  - it contains a peptide turn comprising at least one citrulline residue, and
  - it contains less than 2 amino acids between two cysteine residues, with said citrulline residue being one of the amino acids between said cysteine residues and
  - said peptide is specifically recognised by autoimmune antibodies from patients suffering from rheumatoid arthritis.
- 2. A peptide according to claim 1 characterised in that said peptide is a cyclic peptide.
  - 3. A peptide according to claim 1-2 characterised in that said peptide is biotinylated.
  - 4. A peptide according to claim 1-3 characterised in that said peptide is a synthetic peptide.
  - 5. A peptide according to claim 1-4 characterised in that said peptide contains 4 or 6 residues between the cysteine residues.
  - 6. A peptide according to claim 1-5/characterised in that said peptide has a sequence containing 14, 15, 16, 17 or 18 amino acids.
- 7. A peptide according to claim 1-6 characterised in that said peptide has one of the following primary amino acid structures:



30

- A peptide according to claim 1-7 characterised in that the amino acids flanking 8. the citrulline residue have a small volume and that they do not interact with the citrulline side chain.
- 9. A peptide according to claim 1-8 comprising the amino acid sequence

QDTIHGHPCSXXGHRCGY, or QDTIHGHPCSSXGHRCGY, or QDTIHGHPCSXXGHRCGQ, or QDTIHGHPCSXXGHQCGQ, or QDTIHGHPCSXXGCRPGY, or HGHPCSXXGHRCGY, or HGHPCSXXGCRPGY, or HGHGCDSXGHRCGO, or QDTIVGWGCDSXGCRPGQ, or


QDTIHGHPCSXXGHQCGY or HGHGCDXXGHRCGQ, or VGWGCDSXGCRPGO.

- An antibody raised upon immunisation with a peptide according to any of the 10. claims 1-9, with said antibody being specifically reactive with said peptide and with said antibody being preferably a monoclonal antibody.
- An anti-idiotype antibody/raised upon immunisation with an antibody according 11. 25 to claim 10, with said anti-idiotype antibody being specifically reactive with the antibody of claim 10, thereby mimicking a peptide according to claim 1-9, and with said antibody being preferably a monoclonal antibody.
- A diagnostic kit for use in detecting auto-immune diseases such as rheumatoid 30 12 arthritis, said kit comprising at least one peptide according to any of the claims 1-9, or an

5

10

20



- 13. A diagnostic kit according to claim 12, said kit comprising a range of peptides according to any of claims 1-9 or of antibodies according to any of claims 10 or 11, possibly in combination with antigens that constitute immunogenic determinants for other auto-immune diseases, wherein said peptides are attached to specific locations on a solid substrate.
- 14. A diagnostic kit according to claim 12 or 13, wherein said solid support is a membrane strip and said peptides are coupled to the membrane in the form of parallel lines.
- 15. A diagnostic kit according to claim 12 or 13 wherein certain peptides are not attached to a solid support but are provided in the binding solution to be used as competitors and/or to block other antibodies that are present in sera from patients with autoimmune disease other than rheumatoid arthritis, thereby decreasing or eliminating possible cross-reaction and/or a specific binding.
- 16. Method for producing a peptide according to any of the claims 1-9, by classical chemical synthesis, wherein citrulline residues are substituted for arginine residues at certain steps during the chemical synthesis.
- 17. Method for producing a peptide according to claim 1-9, wherein the primary amino acid sequence is produced by classical chemical synthesis, and wherein at least one arginine residue subsequently is transformed towards a citrulline residue by contacting said peptide with a peptidylarginine deiminase.
  - An immunotoxin molecule comprising a cell recognition molecule being a peptide of any of the claims 1-9, or an antibody according to claims 10 or 11, covalently bound to a toxin molecule or active fragment thereof.

5


20

30

ū

15

5



- 20. Use of a peptide according to claims 1-9 or an antibody according to claim 10 or 11 or an immunotoxin molecule according to claim 18 or a composition thereof for the preparation of a medicament or of a diagnosticum for rheumatoid arthritis.
- 21. Use of a peptide according to claim 1-9 or a composition thereof for the preparation of a medicament to treat autoimmune diseases by increasing the size of antigen-immune complexes, thereby improving the clearance of the formed immune complexes.
- 22. Use of a peptide according to claim 1-9 or a composition thereof for the preparation of a medicament for oral or nasal administration to treat autoimmune diseases by inducing a state of systemic hyporesponsiveness or tolerance to said peptide or composition.